Ganitumab

Last updated
Ganitumab
Monoclonal antibody
Type Whole antibody
Source Human
Target IGF-1R
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6472H10028N1728O2020S42
Molar mass 145712.01 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers. [1] [2]

Ganitumab was developed by Amgen. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012. [3] [4]

References

  1. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab" (PDF). American MedicaAssociation.
  2. ↑ Martínez P, Sales Fidalgo PA, Felip E (October 2014). "Ganitumab for the treatment of small-cell lung cancer". Expert Opinion on Investigational Drugs. 23 (10): 1423–32. doi:10.1517/13543784.2014.951434. PMID   25189625. S2CID   7318164.
  3. ↑ "Amgen Pulls Cancer Drug". 10 Aug 2012. Archived from the original on 2013-07-23.
  4. ↑ "Amgen (AMGN) Terminates Ganitumab Pancreatic Cancer Trial". 8 Aug 2012. Archived from the original on 2012-08-10.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.